Alnylam Pharmaceuticals Company Profile (NASDAQ:ALNY)

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: ALNY
CUSIP: 02043Q10

Key Metrics:

Previous Close: $75.57
50 Day Moving Average: $73.61
200 Day Moving Average: $65.76
52-Week Range: $85,724,000.00 - $49.96
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -14.50
P/E Growth: -0.35
Market Cap: $6.48B
Outstanding Shares: 85,724,000
Beta: 2.39

Profitability:

Net Margins: -1,204.91%
Return on Equity: -29.60%
Return on Assets: -26.12%

Debt:

Debt-to-Equity Ratio: 0.14%
Current Ratio: 12.58%
Quick Ratio: 12.58%

Additional Links:

Companies Related to Alnylam Pharmaceuticals:

Consensus Ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) (?)

Ratings Breakdown:	2 Hold Ratings, 11 Buy Ratings
Consensus Rating:	Buy (Score: 2.85)
Consensus Price Target:	$116.00 (53.50% upside)

Analysts' Ratings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Show:

Date	Firm	Action	Rating	Price Target
9/8/2016	FBR & Co	Reiterated Rating	Buy
9/6/2016	Morgan Stanley	Set Price Target	Buy	$93.00
8/10/2016	Goldman Sachs Group Inc.	Reiterated Rating	Neutral	$63.00 -> $65.00
8/7/2016	Cowen and Company	Reiterated Rating	Buy	$150.00
8/5/2016	Needham & Company LLC	Reiterated Rating	Buy	$152.00
8/5/2016	JPMorgan Chase & Co.	Boost Price Target	Overweight	$80.00 -> $83.00
8/5/2016	Jefferies Group	Boost Price Target	Buy	$80.00 -> $86.00
7/19/2016	Leerink Swann	Reiterated Rating	Buy
7/11/2016	Chardan Capital	Reiterated Rating	Buy
7/10/2016	JMP Securities	Reiterated Rating	Buy
6/12/2016	Credit Suisse Group AG	Reiterated Rating	Buy
5/26/2016	Piper Jaffray Cos.	Reiterated Rating	Buy
11/26/2015	S&P Equity Research	Downgrade	Buy -> Hold
6/24/2015	Deutsche Bank AG	Set Price Target	Buy	$155.00
6/24/2015	Canaccord Genuity	Reiterated Rating	Buy	$160.00
3/17/2015	Janney Montgomery Scott	Initiated Coverage	Buy	$139.00
3/3/2015	Barclays PLC	Initiated Coverage	Overweight	$125.00

(Data available from 9/25/2014 forward)

Earnings History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/7/2016
8/4/2016	Q216	($1.24)	($1.05)	$8.09 million	$8.70 million	View	Listen
5/2/2016	Q116	($1.05)	($1.21)	$7.79 million	$7.30 million	View	Listen
2/11/2016	Q415	($0.96)	($1.07)	$9.59 million	$7.60 million	View	Listen
11/9/2015	Q315	($0.91)	($0.91)	$7.55 million	$6.30 million	View	N/A
8/6/2015	Q215	($0.75)	($0.85)	$12.64 million	$8.69 million	View	N/A
5/7/2015	Q115	($0.66)	($0.62)	$15.40 million	$18.51 million	View	N/A
2/12/2015	Q414	($0.60)	($0.28)	$13.10 million	$24.00 million	View	N/A
11/5/2014	Q314	($0.63)	($0.58)	$8.93 million	$11.00 million	View	N/A
8/7/2014	Q214	($0.56)	($0.63)	$9.36 million	$7.30 million	View	N/A
5/8/2014	Q114	($0.54)	($0.39)	$10.80 million	$8.30 million	View	N/A
2/19/2014	Q413	($0.45)	($0.51)	$9.98 million	$10.80 million	View	N/A
11/6/2013	Q313	($0.39)	($0.48)	$8.64 million	$9.00 million	View	N/A
8/8/2013	Q2 2013	($0.35)	($0.29)	$8.99 million	$8.70 million	View	Listen
5/6/2013	Q1 2013	($0.29)	($0.15)	$15.56 million	$18.60 million	View	Listen
2/7/2013	Q4 2012	($1.45)	($1.20)	$15.82 million	$8.50 million	View	Listen
11/5/2012	Q312	($0.32)	($0.31)	$17.30 million	$16.80 million	View	N/A
8/6/2012		($0.21)	($0.25)			View	N/A
5/3/2012		($0.35)	($0.25)			View	N/A
2/9/2012		($0.33)	($0.33)			View	N/A
11/1/2011		($0.35)	($0.31)			View	N/A
8/1/2011		($0.36)	($0.33)			View	N/A
5/2/2011		($0.30)	($0.38)			View	N/A
2/17/2011		($0.35)	($0.16)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Current Year EPS Consensus Estimate: $-4.65 EPS
Next Year EPS Consensus Estimate: $-5.21 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	($1.14)	($1.08)	($1.11)
Q2 2016	4	($1.32)	($1.19)	($1.26)
Q3 2016	4	($1.35)	($1.25)	($1.30)
Q4 2016	4	($1.41)	($0.96)	($1.26)

(Data provided by Zacks Investment Research)

Dividend History for Alnylam Pharmaceuticals (NASDAQ:ALNY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 85.96%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
7/20/2016	John Maraganore	CEO	Sell	30,151	$64.69	$1,950,468.19
4/20/2016	John Maraganore	CEO	Sell	30,151	$67.46	$2,033,986.46
3/9/2016	Michael W Bonney	Director	Buy	2,000	$58.36	$116,720.00
2/22/2016	David-Alexandre C Gros	SVP	Buy	1,000	$62.75	$62,750.00
2/1/2016	Sanofi	Major Shareholder	Buy	205,030	$69.75	$14,300,842.50
1/20/2016	John Maraganore	CEO	Sell	30,152	$71.78	$2,164,310.56
12/4/2015	Philip A. Sharp	Director	Sell	30,000	$109.00	$3,270,000.00
12/2/2015	John Maraganore	CEO	Sell	58,689	$104.87	$6,154,715.43
11/20/2015	John Maraganore	CEO	Sell	58,690	$102.88	$6,038,027.20
11/12/2015	Kevin P. Starr	Director	Sell	75,000	$103.89	$7,791,750.00
6/16/2015	Akshay Vaishnaw	CMO	Sell	8,750	$128.83	$1,127,262.50
5/12/2015	Michael W Bonney	Director	Buy	2,000	$112.16	$224,320.00
4/21/2015	Paul Schimmel	Director	Sell	10,000	$130.02	$1,300,200.00
3/19/2015	Dennis A Ausiello	Director	Sell	5,000	$120.00	$600,000.00
3/17/2015	Akshay Vaishnaw	CMO	Sell	8,750	$116.86	$1,022,525.00
1/29/2015	Sanofi	Major Shareholder	Buy	97,118	$95.00	$9,226,210.00
1/26/2015	John Maraganore	CEO	Buy	10,000	$95.00	$950,000.00
1/26/2015	Steven M Paul	Director	Buy	1,000	$95.00	$95,000.00
12/19/2014	Barry E Greene	COO	Sell	11,200	$100.00	$1,120,000.00
12/16/2014	Akshay Vaishnaw	EVP	Sell	10,626	$93.60	$994,593.60
12/15/2014	Michael Mason	VP	Sell	22,162	$97.50	$2,160,795.00
11/18/2014	Laurence Reid	SVP	Sell	10,000	$90.67	$906,700.00
11/17/2014	Barry E Greene	COO	Sell	33,200	$89.63	$2,975,716.00
10/28/2014	Paul Schimmel	Director	Sell	15,000	$95.00	$1,425,000.00
10/22/2014	Dennis A Ausiello	Director	Sell	5,000	$90.00	$450,000.00
10/13/2014	Philip A Sharp	Director	Sell	110,000	$85.00	$9,350,000.00
9/25/2014	Kevin P Starr	Director	Sell	90,000	$78.09	$7,028,100.00
9/24/2014	Kevin P Starr	Director	Sell	45,000	$79.08	$3,558,600.00
9/18/2014	John Maraganore	CEO	Sell	113,668	$77.71	$8,833,140.28
9/16/2014	Akshay Vaishnaw	EVP	Sell	10,625	$72.04	$765,425.00
8/18/2014	Laurence Reid	SVP	Sell	13,500	$67.34	$909,090.00
6/26/2014	John Maraganore	CEO	Sell	113,668	$65.45	$7,439,570.60
6/17/2014	Akshay Vaishnaw	EVP	Sell	10,625	$69.82	$741,837.50
5/21/2014	John Clarke	Director	Sell	35,000	$53.80	$1,883,000.00
5/19/2014	Laurence Reid	SVP	Sell	13,500	$57.83	$780,705.00
5/15/2014	John Maraganore	CEO	Sell	113,668	$56.73	$6,448,385.64
3/25/2014	Sanofi	major shareholder	Buy	344,448	$66.88	$23,036,682.24
3/18/2014	Akshay Vaishnaw	EVP	Sell	32,769	$73.95	$2,423,267.55
2/19/2014	Laurence Reid	SVP	Sell	20,400	$80.06	$1,633,224.00
1/24/2014	Akshay Vaishnaw	EVP	Sell	7,890	$85.75	$676,567.50
1/13/2014	Paul Schimmel	Director	Sell	15,000	$85.36	$1,280,400.00
12/20/2013	Paul Schimmel	Director	Sell	15,000	$65.00	$975,000.00
12/17/2013	Akshay Vaishnaw	EVP	Sell	33,480	$60.72	$2,032,905.60
10/22/2013	Paul Schimmel	Director	Sell	15,000	$60.00	$900,000.00
9/11/2013	John Maraganore	CEO	Sell	58,947	$55.50	$3,271,558.50
9/10/2013	Akshay Vaishnaw	EVP	Sell	6,250	$57.48	$359,250.00
8/14/2013	John Maraganore	CEO	Sell	60,000	$48.97	$2,938,200.00
7/12/2013	Michael Mason	VP	Sell	14,200	$50.00	$710,000.00
7/10/2013	John Maraganore	CEO	Sell	60,000	$37.11	$2,226,600.00
7/1/2013	Michael Mason	VP	Sell	27,000	$32.00	$864,000.00
6/17/2013	Michael Mason	VP	Sell	23,625	$29.93	$707,096.25
6/11/2013	Akshay Vaishnaw	EVP	Sell	15,000	$31.08	$466,200.00
5/28/2013	Barry E Greene	COO	Sell	22,822	$30.00	$684,660.00
5/28/2013	Laurence Reid	SVP	Sell	5,000	$30.00	$150,000.00
3/26/2013	Kevin P Starr	Director	Sell	52,631	$23.49	$1,236,302.19
1/22/2013	Philip A Sharp	Director	Buy	4,967	$20.13	$99,985.71

(Data available from 1/1/2013 forward)

Latest Headlines for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Date	Headline
	Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the... (NASDAQ:ALNY) ih.advfn.com - September 25 at 4:43 PM
	Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi ... - Business Wire (press release) (NASDAQ:ALNY) www.businesswire.com - September 25 at 8:12 AM
	Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals ... - Fox Business (NASDAQ:ALNY) www.foxbusiness.com - September 24 at 3:23 PM
	Alnylam Reports Positive Initial Results from Ongoing Phase 1/2 Study of ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (NASDAQ:ALNY) www.publicnow.com - September 24 at 3:23 PM
	Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. - Motley Fool (NASDAQ:ALNY) www.fool.com - September 24 at 8:46 AM
	Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) www.fool.com - September 24 at 8:30 AM
	Alnylam Pharmaceuticals, Inc. Reports Inducement Grant to New Chief Operating Officer (NASDAQ:ALNY) finance.yahoo.com - September 21 at 4:21 PM
	Moderna to build $110 million drug plant in Norwood - The Boston Globe (NASDAQ:ALNY) www.bostonglobe.com - September 21 at 9:43 AM
	3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition -- The ... - Motley Fool (NASDAQ:ALNY) www.fool.com - September 21 at 9:43 AM
	Alnylam to Expand Global Footprint with New European Office in ... - Business Wire (press release) (NASDAQ:ALNY) www.businesswire.com - September 21 at 9:43 AM
	3 Ways Ionis Pharmaceuticals, Inc. Is Beating the Competition - Fox Business (NASDAQ:ALNY) www.foxbusiness.com - September 20 at 3:26 PM
	What are Research Firms Saying About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? - Frisco Fastball (NASDAQ:ALNY) friscofastball.com - September 20 at 3:26 PM
	Alnylam Pharma (ALNY) Makes Two Key Executive Appointments - StreetInsider.com (NASDAQ:ALNY) www.streetinsider.com - September 20 at 3:26 PM
	Alnylam Pharma (ALNY) Makes Two Key Executive Appointments (NASDAQ:ALNY) www.streetinsider.com - September 20 at 9:19 AM
	Alnylam to Expand Global Footprint with New European Office in Maidenhead, UK (NASDAQ:ALNY) www.publicnow.com - September 20 at 9:19 AM
	BRIEF-Alnylam expands and strengthens management team as it plans for commercialization (NASDAQ:ALNY) www.reuters.com - September 19 at 4:22 PM
	Alnylam Expands and Strengthens Management Team as it Plans for Commercialization (NASDAQ:ALNY) www.publicnow.com - September 19 at 4:22 PM
	Global RNA Based Therapeutics Market 2016: Technology, Application, End Users and Geography (NASDAQ:ALNY) www.newsmaker.com.au - September 17 at 8:14 AM
	Alnylam Pharmaceuticals To Participate In BoA Merrill Lynch Conference At 4:00AM (NASDAQ:ALNY) www.nasdaq.com - September 16 at 12:07 PM
	Stock Perspective: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Company Earnings Watch - Frisco Fastball (NASDAQ:ALNY) friscofastball.com - September 13 at 8:16 AM
	Pipeline Insights on Nonalcoholic Steatohepatitis Market (NASDAQ:ALNY) www.bizjournals.com - September 12 at 8:14 AM
	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): What is the Sell-side Making of this Stock? - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - September 8 at 3:25 PM
	Stock Sliding Down Over the Last Month: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - September 7 at 8:33 PM
	CBS 58 - Alnylam Reports Positive Interim Results from Ongoing Phase 1 St (NASDAQ:ALNY) www.cbs58.com - September 7 at 3:25 PM
	Alnylam: ALN-AS1 Phase 1 Study Shows Positive Data, Gets FDA Orphan Drug Status (NASDAQ:ALNY) www.nasdaq.com - September 7 at 3:25 PM
	Alnylam Pharma (ALNY) Announces Positive Interim Data from ALN-AS1 Phase 1 as AHP Treatment - StreetInsider.com (NASDAQ:ALNY) www.streetinsider.com - September 7 at 12:24 PM
	8:17 am Alnylam Pharma reports interim results from ongoing phase 1 study of ALN-AS1, an investigational RNAI therapeutic for the treatment of acute hepatic porphyrias at the 2016 Society for the Study of Inborn Errors of Metabolism Annual (NASDAQ:ALNY) finance.yahoo.com - September 7 at 12:24 PM
	Alnylam Reports Positive Interim Results from Ongoing Phase 1 Study of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (NASDAQ:ALNY) www.publicnow.com - September 7 at 12:24 PM
	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (NASDAQ:ALNY) www.publicnow.com - September 6 at 8:33 PM
	Amyloidosis Pipeline H2 2016 Market Research Report (NASDAQ:ALNY) www.advfn.com - September 5 at 8:13 AM
	Stock Struggling for the Quarter: Alnylam Pharmaceuticals, Inc ... - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - September 4 at 8:12 AM
	Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals - Motley Fool (NASDAQ:ALNY) www.fool.com - September 2 at 3:27 PM
	Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals (NASDAQ:ALNY) www.fool.com - September 2 at 11:49 AM
	Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016, Global Trends, Capacity, Generation, Investment ... - Medgadget (blog) (NASDAQ:ALNY) www.medgadget.com - August 30 at 3:25 PM
	Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - 2016, Global Trends ... (NASDAQ:ALNY) www.medgadget.com - August 30 at 11:51 AM
	Research report explores the Alnylam Pharmaceuticals, Inc. – Product Pipeline Review (NASDAQ:ALNY) www.medgadget.com - August 29 at 9:06 PM
	Research report explores the Alnylam Pharmaceuticals, Inc. - Product Pipeline Review - Medgadget (blog) (NASDAQ:ALNY) www.medgadget.com - August 27 at 8:13 AM
	How is the Crowd Rating Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - August 24 at 3:27 PM
	ETF’s with exposure to Alnylam Pharmaceuticals, Inc. : August 24, 2016 (NASDAQ:ALNY) www.capitalcube.com - August 24 at 3:27 PM
	Amyloid-related heart failure now detectable with imaging test (NASDAQ:ALNY) scienmag.com - August 24 at 11:42 AM
	Alnylam Pharmaceuticals Has Returned 24.1% Since SmarTrend Recommendation (ALNY) (NASDAQ:ALNY) www.mysmartrend.com - August 24 at 11:42 AM
	Stock Trading Above Moving Averages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - August 22 at 8:35 PM
	Can Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Keep Up With Analyst Expectations? - Investor Newswire (NASDAQ:ALNY) www.investornewswire.com - August 22 at 3:28 PM
	Stock Gaining Over the Past Six Months: Alnylam Pharmaceuticals ... - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - August 21 at 3:24 PM
	Sell-side Price Target Review on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - August 21 at 8:12 AM
	Shares Holding Above Moving Averages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - August 20 at 8:25 AM
	Analysts See Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ... - RealistInvestor.com (NASDAQ:ALNY) www.realistinvestor.com - August 18 at 3:33 PM
	Crowd Perspectives & Analyst Views on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? - Post News (NASDAQ:ALNY) www.kentuckypostnews.com - August 17 at 3:28 PM
	Uptrend Call Working As Alnylam Pharmaceuticals Stock Rises 21.8% (ALNY) (NASDAQ:ALNY) www.mysmartrend.com - August 16 at 3:27 PM
	Alnylam Pharmaceuticals, Inc. Cranks Out the Data - Motley Fool (NASDAQ:ALNY) www.fool.com - August 13 at 3:25 PM